Trials / Completed
CompletedNCT04485039
Drug-drug Interaction Study of TPOXX When Co-administered With Phosphate Binders
A Post-Marketing Open-Label, 5 Period Crossover, Drug-Drug Interaction Study of Orally Adminstered TPOXX When Co-administered With 4 Different Phosphate Binders in Healthy Subjects
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 44 (actual)
- Sponsor
- SIGA Technologies · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
An open-label, drug-drug interaction study with TPOXX and phosphate binders.
Detailed description
A postmarketing open-label, 5 period crossover, drug-drug interaction study of orally administered TPOXX when coadministered with 4 different phosphate binders in healthy adult subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tecovirimat | oral antiviral |
| DRUG | sevelamer carbonate oral tablet | phosphate binder |
| DRUG | sucroferric oxyhydroxide chewable tablet | phosphate binder |
| DRUG | calcium acetate oral tablet | phosphate binder |
| DRUG | Lanthanum Carbonate Chewable Tablet | phosphate binder |
Timeline
- Start date
- 2022-06-08
- Primary completion
- 2022-12-15
- Completion
- 2023-04-23
- First posted
- 2020-07-24
- Last updated
- 2024-12-27
- Results posted
- 2024-10-09
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04485039. Inclusion in this directory is not an endorsement.